Koloski, Natasha http://orcid.org/0000-0002-8647-5933
Shah, Ayesha http://orcid.org/0000-0003-0710-1691
Kaan, Iain http://orcid.org/0000-0002-8069-1264
Ben Jacob, Ronen http://orcid.org/0000-0003-2580-4294
Talley, Nicholas J. http://orcid.org/0000-0003-2537-3092
Jones, Michael P. http://orcid.org/0000-0003-0565-4938
Holtmann, Gerald http://orcid.org/0000-0002-0206-2358
Funding for this research was provided by:
Allergan Australia
The University of Queensland
Article History
Received: 12 April 2023
Accepted: 22 September 2023
First Online: 24 February 2024
Declarations
:
: Natasha Koloski, Ayesha Shah, Ronen Ben Jacob, and Michael P. Jones disclose no conflicts. Iain Kaan is a former employee of AbbVie. Nicholas J Talley's disclosures include Intrinsic Medicine (2022) (human milk oligosaccharide), Alimentry (2023) (gastric mapping), Agency for Health Care Research and Quality (fiber and laxation) (2024), outside the submitted work. In addition, Dr. Talley has a patent Nepean Dyspepsia Index (NDI) 1998, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, “Diagnostic marker for functional gastrointestinal disorders” Australian Provisional Patent Application 2021901692, “Methods and compositions for treating age-related neurodegenerative disease associated with dysbiosis” US Patent Application No. 63/537,725. Financial support: Dr. Talley is supported by funding from the National Health and Medical Research Council (NHMRC) to the Centre for Research Excellence in Digestive Health and he holds an NHMRC Investigator grant and a research grant from Defence. Gerald Holtmann received unrestricted educational support from the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies Pty Ltd, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty Ltd, F. Hoffmann-La Roche Ltd, MedImmune Ltd, Celgene Pty Ltd, Celgene International II Sarl, Gilead Sciences Pty Ltd, Quintiles Pty Ltd, Vital Food Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Ltd, Prometheus Laboratories, FALK GmbH & Co KG, Nestle Pty Ltd, Mylan, and Allergan (prior to acquisition by AbbVie Inc.). Dr. Holtmann is also a patent holder for a biopsy device to take aseptic biopsies (US 20150320407 A1).